Hostname: page-component-76fb5796d-45l2p Total loading time: 0 Render date: 2024-04-26T16:29:34.752Z Has data issue: false hasContentIssue false

Clinical Trials in Schizophrenia with Results for the Real World

Published online by Cambridge University Press:  07 November 2014

Diana O. Perkins*
Affiliation:
Dr. Perkins is a professor of psychiatry in the Department of Psychiatry at the, University of North Carolina School of Medicine in Chapel Hill
*
Diana O. Perkins, MD, MPH, Department of Psychiatry, CB 7160, University of North Carolina School of Medicine, Chapel Hill NC 27514; Tel: 919-966-3813; Fax:, 919-966-8004; E-mail:, Diana_Perkins@med.unc.edu

Abstract

Most clinical data for antipsychotics come from studies designed to test the efficacy and safety of the drugs under ideal conditions, in limited subgroups of patients. In contrast, practical clinical trials (PCTs) are designed to test the effectiveness of different treatment options under conditions that more accurately reflect actual clinical practice. Consequently, PCTs are able to provide information that can be utilized by healthcare providers and other decision makers. Characteristics of PCTs include a clinically relevant question, a representative sample of patients and practice settings, sufficient power to identify modest relevant effects, randomization to protect against bias, uncertainty regarding the outcome of treatment, assessment and treatment protocols that enact best clinical practices, simple and relevant outcomes, and limited subject and investigator burden. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) research program is an example of a PCT. The CATIE study illustrates how PCTs, when properly designed, might be helpful in informing clinical decision making. Because the CATIE study was designed to reflect the effectiveness of antipsychotics under naturalistic clinical conditions, its results should have particular applicability to the arena of clinical practice. This article provides a discussion of the differences between efficacy and effectiveness studies. In assessing the practical utility of results from the CATIE study, much can be learned on how to shape future studies of effectiveness so as to better generate data that are applicable to the “real world.”

Type
Research Article
Copyright
Copyright © Cambridge University Press 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Lieberman, J, Stroup, TS, McEvoy, JP, et al.Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Eng J Med. 2005;353:12091223.CrossRefGoogle ScholarPubMed
2.Jaffe, AB, Levine, J. Efficacy and effectiveness of first- and second-generation antipsychotics in schizophrenia. J Clin Psychiatry. 2003;64[suppl 17]:36.Google ScholarPubMed
3.March, JS, Silva, SG, Compton, S, Shapiro, M, Califf, R, Krishnan, R. The case for practical clinical trials in psychiatry. Am J Psychiatry. 2005;162:836846.CrossRefGoogle ScholarPubMed
4.Tunis, SR, Stryer, DB, Clancy, CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003;290:16241632.CrossRefGoogle ScholarPubMed
5.Klein, DF, Thase, ME, Endicott, J, et al.Improving clinical trials: American Society of Clinical Psychopharmacology recommendations. Arch Gen Psychiatry. 2002;59:272278.CrossRefGoogle ScholarPubMed
6.Stroup, TS, McEvoy, JP, Swartz, MS, et al.The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophrenia Bull. 2003;29:1531.CrossRefGoogle ScholarPubMed
7. National Institute of Mental Health Alliance for Research Progress. Minutes of meeting of July 19, 2004, Bethesda, MD. Available at: http://www.nimh.nih.gov/outreach/AllianceReport2004.pdf. Accessed: February 15, 2005.Google Scholar
8.Swartz, MS, Perkins, DO, Stroup, TS, McEvoy, JP, Nieri, JM, Haak, DC. Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. Schizophrenir Bull. 2003;29:3343.CrossRefGoogle ScholarPubMed
9.Goff, DC, Sullivan, LM, McEvoy, JP, et al.A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res. 2005;80:4553.CrossRefGoogle ScholarPubMed
10.McEvoy, JP, Meyer, JM, Goff, DC, et al.Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80:1932.CrossRefGoogle ScholarPubMed
11.Meyer, JM, Nasrallah, HA, McEvoy, JP, et al.The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res. 2005;80:918.CrossRefGoogle ScholarPubMed
12.Sackett, DL, Rosenberg, WMC, Gray, JAM, Haynes, RB, Richardson, WS. Evidence based medicine: what it is and what it isn't. BMJ. 1996;312:7172.CrossRefGoogle ScholarPubMed